Clinical research emphasizes the implementation of rigorous and reproducible study designs that rely on between-group matching or controlling for sources of biological variation such as subject's sex and age. However, corrections for body size (i.e. height and weight) are mostly lacking in clinical neuroimaging designs. This study investigates the importance of body size parameters in their relationship with spinal cord (SC) and brain magnetic resonance imaging (MRI) metrics. Data were derived from a cosmopolitan population of 267 healthy human adults (age 30.1±6.6 years old, 125 females). We show that body height correlated strongly or moderately with brain gray matter (GM) volume, cortical GM volume, total cerebellar volume, brainstem volume, and cross-sectional area (CSA) of cervical SC white matter (CSA-WM; 0.44≤r≤0.62). In comparison, age correlated weakly with cortical GM volume, precentral GM volume, and cortical thickness (-0.21≥r≥-0.27). Body weight correlated weakly with magnetization transfer ratio in the SC WM, dorsal columns, and lateral corticospinal tracts (-0.20≥r≥-0.23). Body weight further correlated weakly with the mean diffusivity derived from diffusion tensor imaging (DTI) in SC WM (r=-0.20) and dorsal columns (-0.21), but only in males. CSA-WM correlated strongly or moderately with brain volumes (0.39≤r≤0.64), and weakly with precentral gyrus thickness and DTI-based fractional anisotropy in SC dorsal columns and SC lateral corticospinal tracts (-0.22≥r≥-0.25). Linear mixture of sex and age explained 26±10% of data variance in brain volumetry and SC CSA. The amount of explained variance increased at 33±11% when body height was added into the mixture model. Age itself explained only 2±2% of such variance. In conclusion, body size is a significant biological variable. Along with sex and age, body size should therefore be included as a mandatory variable in the design of clinical neuroimaging studies examining SC and brain structure.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11092490 | PMC |
http://dx.doi.org/10.1101/2024.04.29.591421 | DOI Listing |
Alzheimers Dement
December 2024
Faculty of Medicine, University of Oslo, Oslo, Norway.
Background: While symptomatic treatment for Alzheimer's disease has been available for three decades disease modifying treatment does not exist. New drug treatments, known as immunotherapies, which remove amyloid from the brain offer hope, but the clinical significance remains uncertain.
Method: Systematic reviews of the literature, expert consensus, and information from clinical environments.
Ann Med
December 2025
Department of Nursing, Faculty of Health Sciences of Ceuta, University of Granada, Ceuta, Spain.
Objective: To establish a new technique to easily identify the fetal cervix-uterus complex in normal female fetuses from 20 to 40 weeks of gestation.
Material And Methods: The study was performed in routine examination in normal fetuses by two observers. Twenty-five consecutive cases per gestational week were assessed between 20 and 40 weeks.
Alzheimers Dement
December 2024
Universidade Federal de Pernambuco, Recife, Brazil.
Introduction: Dementia numbers are increasing rapidly with a substantial contribution from low and middle-income countries. There's a limited number of reports in Brazil, mostly modest initiatives from south-eastern, more developed regions. With a population of approximately 1.
View Article and Find Full Text PDFAnn Surg
January 2025
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Objective: To investigate the clinicopathological features and long-term outcomes of cystic and solid pancreatic neuroendocrine tumors (PanNETs).
Summary Background Data: PanNETs uncommonly present as cystic lesions. Whether cystic PanNETs represent a distinct clinical entity compared to solid PanNETs is controversial.
Med J Islam Repub Iran
September 2024
Burn Research Center, Shahid Motahari Hospital, Iran University of Medical Sciences, Tehran, Iran.
Background: Treatment of hypertrophic burn scars is challenging. Intralesional injection of corticosteroids has been the first line of treatment. Triamcinolone Acetonide (TA) and Bleomycin (BLE) are standard therapeutic options.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!